Behcet's disease. Behcet's disease
Conditions
Interventions
Intervention 1: Intervention group: nanocurcumin Patients in intervention group will take one 80 mg nanocurcumin capsule (produced by Exi
Sponsors
Connective Tissue Diseases Research Center
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Willingness to cooperate Age range 20 to 60 years Diagnosis of Behcet's disease by rheumatologist
Exclusion criteria
Exclusion criteria: Use of nutritional supplements and antioxidant and alpha-lipoic acid during a month before the study Pregnancy and lactation History of diabetes and other chronic diseases The history of other autoimmune diseases Admission rate less than 70% of supplemental intake Smoking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The expression of miRNAs. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;Frequency of Th17 cells. Timepoint: Before and after intervention. Method of measurement: Flow cytometry.;The expression of the RoR?. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;IL-23 and IL-17 cytokine gene expression. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;The level of IL-23 and IL-17 cytokine secretion. Timepoint: Before and after intervention. Method of measurement: Elisa.;Frequency of Treg cells. Timepoint: Before and after intervention. Method of measurement: Flow cytometry.;The expression of the Foxp3. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;TGF-b and IL-10 cytokine gene expression. Timepoint: Before and after intervention. Method of measurement: QRT-PCR.;The level of TGF-b and IL-10 cytokine secretion. Timepoint: Before and after intervention. Method of measurement: Elisa. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehdi Yousefi
Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Outcome results
None listed